UAE becomes first in world to approve new oral vitiligo drug

The United Arab Emirates has become the first country globally to approve the expanded use of the oral medication RINVOQ (upadacitinib) for treating non-segmental vitiligo, a skin condition characterized by loss of skin color in patches. The Emirates Drug Establishment (EDE) announced on Monday that RINVOQ can now be prescribed for adults and adolescents aged 12 years and above who require systemic therapy for their condition.

This development marks a significant milestone in providing patients with an additional, convenient treatment option. RINVOQ is administered as a once-daily pill, allowing for easier adherence to the treatment regimen compared to other systemic therapies. This approval underscores the UAE's commitment to embracing cutting-edge pharmaceutical innovations and expediting patient access to them, positioning the country as a global leader in healthcare advancements.

The Emirates Drug Establishment emphasized that this regulatory decision aligns with an advanced framework that keeps pace with global scientific developments, bolstering the nation's pharmaceutical sector and enhancing treatment outcomes for vitiligo patients. Vitiligo, an autoimmune skin disorder, results in the loss of skin pigment, leading to white or pale patches appearing on various body parts.

The condition is believed to stem from immune system dysfunction, potentially influenced by genetic factors, environmental triggers, sun or chemical exposure, stress, and physical trauma. Non-segmental vitiligo, the most prevalent form, presents symmetrical patches that gradually expand over time, while segmental vitiligo, affecting around 10% of cases, involves smaller, localized patches on one side of the body, tends to manifest earlier, and often stabilizes more quickly.

The causes of vitiligo remain largely unknown, but it is generally regarded as an autoimmune condition wherein the immune system erroneously targets and destroys melanocytes, the skin cells responsible for producing pigment. Research suggests a link between vitiligo and other autoimmune disorders such as thyroid disease, psoriasis, rheumatoid arthritis, alopecia areata, and diabetes, although the precise etiology remains unclear.

Vitiligo affects approximately 0.5 to 1% of the global population, with estimates potentially reaching as high as 1.5%, considering the significant number of unreported cases. The onset of vitiligo typically occurs during the mid-twenties, although it can manifest at any age. World Vitiligo Day, observed annually on June 25, serves as a platform to raise awareness about the condition, provide support to affected individuals, and advocate for improved access to diagnosis, treatment, and mental health resources worldwide.

The date was selected to commemorate Michael Jackson, who publicly disclosed his vitiligo diagnosis on that very day in 2009, drawing international attention to the plight of vitiligo patients. Beyond its physical manifestations, vitiligo often engenders considerable psychological distress, with many patients grappling with anxiety, diminished self-esteem, and societal stigma.

Consequently, proactive mental health support is deemed equally crucial as medical intervention for holistic patient well-being.